Chemical reactivity, molecular docking and ADMET profile of (E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid molecule: evaluation as a diabetes drug candidate | Synapse
March 3, 2026
Chemical reactivity, molecular docking and ADMET profile of (E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid molecule: evaluation as a diabetes drug candidate
Key Points
The findings indicate promising chemical reactivity and molecular docking results for the drug candidate.
A favorable ADMET profile is achieved, demonstrating good absorption and low toxicity when tested.
Evaluation employs molecular docking techniques to predict interactions with diabetes-related targets.
This novel compound may serve as a promising candidate for diabetes treatment, warranting further exploration.